Pyrotinib
08 Jun 2021
PYRAMID-1
NCT04447118
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy.
Jiangsu HengRui Medicine Co., Ltd.
Cancer Type | Lung & mesothelioma |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | Urothelial |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2020-09-11 |
Anticipated End Date | 2023-10-31 |
Hospital | Calvary Central Districts Hospital |
---|---|
Clinical Trial Coordinator | Julie Rowe |
julie.rowe@calvarycare.org.au | |
Phone | 08 8239 9536 |
Principal Investigator | Dr Rohit Joshi |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs